Brian Zahab

The anti-myeloma effects of the selective JAK1 inhibitor (INCB052793) alone and in combination in vitro and in vivo

Saurabh Patil, Haiming Chen, J. Berenson, 2019, Annals of Hematology.

Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells.

N. Xu, T. Spektor, Saurabh Patil, 2019, Leukemia research.

JAK1/2 pathway inhibition suppresses M2 polarization and overcomes resistance of myeloma to lenalidomide by reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 expression

N. Xu, T. Spektor, Haiming Chen, 2020, British journal of haematology.

The JAK Inhibitor Blocks PD-L1, PD-L2 and CD44 Expression in Multiple Myeloma (MM) and Sensitizes MM Cells to Lenalidomide and Steroids

Haiming Chen, J. Berenson, George Y Tang, 2018, Blood.

The anti-myeloma effects of the selective JAK1 inhibitor (INCB052793) alone and in combination in vitro and in vivo

Saurabh Patil, Haiming Chen, J. Berenson, 2019, Annals of Hematology.